

ANNALS OF
FAMILY MEDICINE
 Online Supplementary Material

Hayward G, Heneghan C, Perera R, Thompson M. Intranasal corticosteroids in management of acute sinusitis: a systematic review and meta-analysis. *Ann Fam Med.* 2012;10(3):241-249.

<http://www.annfammed.org/content/10/3/241>

Supplemental Appendix. Mean Individual Symptom Scores Reported for Study and Dosage Arm

Outcome and Study	MFNS Dose, µg	Steroid			Placebo			P Value
		Base-line	Average Day 1-15	Reduction	Base-line	Average Day 1-15	Reduction	
Facial pain								
Meltzer et al ¹ (2005)	200	1.31	0.57	0.74	1.32	0.64	0.68	NS
Meltzer et al ¹ (2005)	400	1.29	0.52	0.77	1.32	0.64	0.68	< .05
Nayak et al ² (2002)	400	1.83	0.85	0.98	1.79	0.95	0.84	NS
Nayak et al ² (2002)	800	1.89	0.89	1.03	1.79	0.95	0.84	.008
Meltzer et al ³ (2000)	800	1.92	0.76	1.16	1.92	0.98	0.94	< .01
Congestion								
Meltzer et al ¹ (2005)	200	2.06	1.06	1.00	2.04	1.25	0.79	< .001
Meltzer et al ¹ (2005)	400	2.02	0.94	1.08	2.04	1.25	0.79	< .001
Nayak et al ² (2002)	400	2.35	1.25	1.10	2.34	1.40	0.94	.01
Nayak et al ² (2002)	800	2.28	1.20	1.08	2.34	1.40	0.94	.025
Meltzer et al ³ (2000)	800	2.29	1.25	1.04	2.22	1.42	0.80	< .01
Headache								
Meltzer et al ¹ (2005)	200	1.34	0.64	0.70	1.39	0.68	0.71	NS
Meltzer et al ¹ (2005)	400	1.38	0.57	0.81	1.39	0.68	0.71	< 0.01
Nayak et al ² (2002)	400	1.79	0.84	0.95	1.87	0.92	0.95	NS
Nayak et al ² (2002)	800	1.82	0.87	0.95	1.87	0.92	0.95	NS
Meltzer et al ³ (2000)	800	1.71	0.71	1.00	1.78	0.93	0.85	NS
Rhinorrhea								
Meltzer et al ¹ (2005)	200	1.66	0.89	0.77	1.76	1.04	0.72	< .001
Meltzer et al ¹ (2005)	400	1.72	0.81	0.91	1.76	1.04	0.72	< .001
Nayak et al ² (2002)	400	1.99	0.94	1.05	2.04	1.08	0.96	NS
Nayak et al ² (2002)	800	2.02	0.92	1.10	2.04	1.08	0.96	.045
Meltzer et al ³ (2000)	800	1.91	0.89	1.02	1.86	0.96	0.90	NS

Continued.

Supplemental Appendix, *continued*.

Outcome and Study	MFNS Dose, µg	Steroid			Placebo			P Value
		Base-line	Average Day 1-15	Reduction	Base-line	Average Day 1-15	Reduction	
Postnasal drip								
Meltzer et al ¹ (2005)	200	1.80	1.00	0.80	1.87	1.04	0.83	NS
Meltzer et al ¹ (2005)	400	1.88	0.95	0.93	1.87	1.04	0.83	NS
Nayak et al ² (2002)	400	2.20	1.17	1.03	2.17	1.28	0.89	.04
Nayak et al ² (2002)	800	2.11	1.12	0.99	2.17	1.28	0.89	NS
Meltzer et al ³ (2000)	800	2.20	0.15	0.95	2.12	0.22	0.90	NS

MFNS = mometasone furoate nasal spray; NS = not significant.
 Note: Possible symptom scores range from 0 (none) to 3 (severe).

References

1. Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. *J Allergy Clin Immunol.* 2005;116(6):1289-1295.
2. Nayak AS, Settipane GA, Pedinoff A, et al; Nasonex Sinusitis Group. Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. *Ann Allergy Asthma Immunol.* 2002;89(3):271-278.
3. Meltzer EO, Charous BL, Busse WW, Zinreich SJ, Lorber RR, Danzig MR; The Nasonex Sinusitis Group. Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray [see comment]. *J Allergy Clin Immunol.* 2000;106(4):630-637.